Shipley Lisa
Bioanalysis. 2013 Aug;5(15):1819-20. doi: 10.4155/bio.13.129.
Lisa Shipley is Vice President of Pharmacokinetics, Pharmacodynamics and Drug Metabolism at Merck Research Laboratories. She is responsible for preclinical and clinical ADME activities and molecular biomarker assay development activities at all Merck research sites and support of all programs from discovery through to post-product launch. Prior to joining Merck in 2008, Shipley spent over 20 years at Eli Lilly and Company in roles of increasing responsibility, including the positions of executive director at Lean Six Sigma and vice president of Drug Disposition, PK/PD and Trial Simulations. Shipley obtained her undergraduate degree from McDaniel College and her doctoral degree in Pharmacology and Toxicology from the University of Maryland at Baltimore. This interview was conducted by Lisa Parks, Assistant Commissioning Editor of Bioanalysis.
丽莎·希普利是默克研究实验室药代动力学、药效学和药物代谢副总裁。她负责默克所有研究地点的临床前和临床药物代谢动力学、药效学及药物代谢（ADME）活动以及分子生物标志物检测方法开发活动，并为从发现到产品上市后的所有项目提供支持。在2008年加入默克之前，希普利在礼来公司工作了20多年，职位不断晋升，包括精益六西格玛执行董事以及药物处置、药代动力学/药效学和试验模拟副总裁等职位。希普利在麦克丹尼尔学院获得本科学位，并在巴尔的摩的马里兰大学获得药理学和毒理学博士学位。本次采访由生物分析助理委托编辑丽莎·帕克斯进行。
